URB #426 — The Gold Standard Category Error: Pragmatic Efficacy vs. Mechanistic Attribution in Drug Approval

The randomized, double-blind, placebo-controlled trial, often called the gold standard of medical evidence, answers whether an intervention's effect is caused by its pharmacological mechanism rather than by expectation or bias. This mechanistic attribution question is legitimate but distinct from the pragmatic efficacy question: whether the intervention produces net positive outcomes for patients. Medical regulation conflates these, requiring mechanistic proof before allowing pragmatic access. Psychedelic research exemplifies this: psychedelics cannot be double-blinded because their subjective effects are unmistakable, yet this methodological limitation is used to block access to treatments that help patients. The paper argues this conflation is a category error with serious consequences, and that pragmatic access should be permitted on pragmatic evidence without requiring mechanistic certainty.

Study at a glance

Abstract

The randomized, double-blind, placebo-controlled trial (RCT) — "the gold standard of medical evidence" — was designed to answer a specific epistemic question: is the observed effect of an intervention causally attributable to the intervention's pharmacological mechanism rather than to expectation, observer bias, or selection effects? This is the **mechanistic attribution question**. It is a legitimate scientific question. It is, however, a completely different question from the **pragmatic efficacy question**: does this intervention produce net positive outcomes for patients who receive it? Medical regulatory frameworks have systematically conflated these two questions — requiring an affirmative answer to the mechanistic question before permitting access to the pragmatic benefit. The placebo-control criterion for psychedelic research exemplifies this conflation at its most consequential and most perverse: psychedelics cannot be adequately double-blinded because the subjective experience is unmistakable, and this methodological fact is used to indefinitely delay access to treatments that demonstrably help patients. This paper argues that the conflation is a category error — a philosophical error with life-and-death consequences — and that the correct epistemic framework separates pragmatic and mechanistic questions, answers each with appropriate methods, and permits pragmatic access on pragmatic evidence without requiring mechanistic certainty as a precondition.